Response to: ‘Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment considered’

• Elio Novembre,
• Mariannita Gelsomino,
• Lucia Liotti,
• Simona Barni,
• Francesca Mori,
• Mattia Giovannini,
• Carla Mastrorilli,
• Luca Pecoraro,
• Francesca Saretta,
• Riccardo Castagnoli,
• Stefania Arasi,
• Lucia Caminiti,
• Angela Klain,
• Michele Miraglia del Giudice

Affiliations

Elio Novembre

Department of Health Sciences, University of Florence

Mariannita Gelsomino

Department of Life Sciences and Public Health, Pediatric Allergy Unit, University Foundation Policlinico Gemelli IRCCS Catholic University of the Sacred Heart

Lucia Liotti

Pediatric Unit, Department of Mother and Child Health, Salesi Children’s Hospital

Simona Barni

Allergy Unit, Meyer Children’s Hospital IRCCS

Francesca Mori

Allergy Unit, Meyer Children’s Hospital IRCCS

Mattia Giovannini

Department of Health Sciences, University of Florence

Carla Mastrorilli

Pediatric Hospital Giovanni XXIII, Pediatric and Emergency Department, AOU Policlinic of Bari

Luca Pecoraro

Pediatric Unit, Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona

Francesca Saretta

Pediatric Department, Latisana-Palmanova Hospital, Azienda Sanitaria Universitaria Friuli Centrale

Riccardo Castagnoli

Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia

Stefania Arasi

Translational Research in Pediatric Specialties Area, Division of Allergy, Bambino Gesù Children’s Hospital, IRCCS

Lucia Caminiti

Allergy Unit, Department of Pediatrics, AOU Policlinico Gaetano Martino

Angela Klain

Department of Woman, Child and General and Specialized Surgery, University of Campania “Luigi Vanvitelli”

Michele Miraglia del Giudice

Department of Woman, Child and General and Specialized Surgery, University of Campania “Luigi Vanvitelli”